Challenges and Successes in Developing Effective Anti-angiogenic Agents

摘要: Although the concept of tumors having a distinct capillary network and blood supply was first described by Virchow in 1863, intensively studied Goldman 1907 [1], many decades passed before Judith Folkman discovered that angiogenesis vascularization were critical to tumor growth metastasis 1971 [2–4]. In 1973, endothelial cells derived from human umbilical veins successfully cultured [5], leading angiogenic bioassay, vivo model development, discovery factors [6]. The potential inhibition as anti-cancer therapy elicited an explosion research 1970s; however, there would be difficulties, failures, delays translating this new class agents clinical trials. late 1980s, anti-angiogenic properties low-dose interferon used treating hemangiomas angioblastomas [7], thalidomide’s became beneficial multiple myelomas 1999 [8].